FIDIA PHARMACEUTICAL HAS AT LEAST TWO DRUGS IN PHASE II CLINICALS
FIDIA PHARMACEUTICAL HAS AT LEAST TWO DRUGS IN PHASE II CLINICALS, Cronassial for the treatment of peripheral neuropathies, and monosialoganglioside GM to enhance recovery of central nervous system damage due to stroke and for potential use in spinal cord injuries. The Phase II Cronassial trials are expected to be completed by the end of 1985. Six studies are currently ongoing. The firm asserts that Cronassial, "an injectable form of highly purified gangliosides, is among the world's top 200 products and is the leading peripheral neuropathy product in Italy." Established in July, Fidia Pharmaceutical, based in Washington, D.C., is a whollyowned subsidiary of the Italian firm Fidia, S.p.A. In a Nov. 22 press release, the Italian company explained that formation of the U.S. unit is part of its effort "to establish reference points on important foreign markets." Fidia S.p.A. explained in the press release that the objectives of the affiliate are to "encourage clinical research and coordinate clinical investigations" and to "provide for regulatory development of Fidia's original drugs; in particular to proceed to submission of NDAs for the products in development." The U.S. affiliate is headed by the parent's former clinical data center director Danilo Casadei Massari. As president of the U.S. unit, Massari heads a staff of nine, including two VPs. The staff will expand to 12 during 1985. The 35-year old parent, Fidia S.p.A., is primarily involved in neurologic drugs for use in cardiology, wound healing and arthritis. The company noted that other products in the pipeline for IND submissions in the U.S. are phosphatidylserine for the treatment of "brain organic syndrome" and hyaluronic acid. The firm added it is developing a "specific fraction of hyaluronic acid, obtained by an innovative process, for the intra-articular treatment of human degenerative joint disease." Fidia S.p.A. stated that "the considerable research interest in the U.S.A. in these new leads warranted the direct involvement and investment represented" by the new affiliate.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth